share_log

ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Shareholders Respectable 19% CAGR Over 3 Years, Surging 5.9% in the Last Week Alone

ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Shareholders Respectable 19% CAGR Over 3 Years, Surging 5.9% in the Last Week Alone

ANI Pharmicals(纳斯达克股票代码:ANIP)在3年内为股东带来了可观的19%的复合年增长率,仅在上周就飙升了5.9%
Simply Wall St ·  2023/12/13 05:31

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) shareholders might be concerned after seeing the share price drop 19% in the last quarter. But don't let that distract from the very nice return generated over three years. In fact, the company's share price bested the return of its market index in that time, posting a gain of 68%.

ANI制药公司(纳斯达克股票代码:ANIP)股东在看到上个季度股价下跌19%后可能会感到担忧。但是,不要让这分散人们对三年来产生的非常可观的回报的注意力。实际上,该公司的股价在当时超过了其市场指数的回报率,涨幅为68%。

After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals.

在过去一周强劲上涨之后,值得一看的是长期回报是否是由基本面改善推动的。

Check out our latest analysis for ANI Pharmaceuticals

查看我们对ANI Pharmicals的最新分析

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

引用巴菲特的话说:“船只将在世界各地航行,但平地协会将蓬勃发展。市场上的价格和价值之间将继续存在巨大差异...”通过比较每股收益(EPS)和股价随时间推移的变化,我们可以了解投资者对公司的态度如何随着时间的推移而变化。

During three years of share price growth, ANI Pharmaceuticals moved from a loss to profitability. That would generally be considered a positive, so we'd expect the share price to be up.

在三年的股价增长中,ANI Pharmicals从亏损转为盈利。这通常会被视为利好,因此我们预计股价会上涨。

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

你可以在下面看到 EPS 是如何随着时间的推移而发生的变化(点击图片发现确切的数值)。

earnings-per-share-growth
NasdaqGM:ANIP Earnings Per Share Growth December 13th 2023
纳斯达克通用汽车公司:ANIP 每股收益增长 2023 年 12 月 13 日

We know that ANI Pharmaceuticals has improved its bottom line lately, but is it going to grow revenue? If you're interested, you could check this free report showing consensus revenue forecasts.

我们知道ANI Pharmicals最近提高了利润,但它会增加收入吗?如果你感兴趣,可以查看这份显示共识收入预测的免费报告。

A Different Perspective

不同的视角

It's good to see that ANI Pharmaceuticals has rewarded shareholders with a total shareholder return of 27% in the last twelve months. That's better than the annualised return of 3% over half a decade, implying that the company is doing better recently. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. It's always interesting to track share price performance over the longer term. But to understand ANI Pharmaceuticals better, we need to consider many other factors. For example, we've discovered 3 warning signs for ANI Pharmaceuticals that you should be aware of before investing here.

很高兴看到ANI Pharmicals在过去十二个月中向股东提供了27%的总股东回报率。这比五年来3%的年化回报率要好,这意味着该公司最近的表现更好。鉴于股价势头仍然强劲,可能值得仔细研究该股,以免错过机会。长期跟踪股价表现总是很有意思的。但是,为了更好地了解ANI Pharmicals,我们需要考虑许多其他因素。例如,我们发现了ANI Pharmicals的3个警告信号,在投资之前,您应该注意这些信号。

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

对于那些喜欢寻找中奖投资的人来说,这份最近有内幕收购的成长型公司的免费名单可能只是门票。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

请注意,本文引用的市场回报反映了目前在美国交易所交易的股票的市场加权平均回报率。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是笼统的。我们仅使用公正的方法提供基于历史数据和分析师预测的评论,我们的文章并非旨在提供财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不会考虑最新的价格敏感型公司公告或定性材料。华尔街只是没有持有上述任何股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发